title: Gonadotropin-dependent expression of sterol 14-demethylase P450 (CYP51) in rat ovaries and its contribution to the production of a meiosis-activating steroid.
abstract: Immunohistochemical analysis showed that sterol 14-demethylase P450 (CYP51) is expressed in mature follicles and corpus lutea of rat ovaries. In follicles, CYP51 is expressed in granulosa and theca cells but not in oocytes. The ovarian CYP51 activity of hypophysectomized rats is very low and induced by pregnant mares' serum gonadotropin (PMSG) treatment together with ovarian growth. The expression of CYP51 first increases in growing follicles and then appears in the corpus lutea after luteinization. The former event may be due to the follicular-stimulating hormone action of PMSG, and the latter may be caused by the luteinizing hormone effect of PMSG. Sterol analysis indicated that the product of the CYP51-mediated lanosterol 14-demethylation, 4,4-dimethylcholesta-8,14,24-trienol, which has been identified as a meiosis-activating steroid (MAS) in mammals [Byskov et al. (1995) Nature 374, 559-562], accumulates (about 10 pmol/mg of ovary) in mature rat ovaries, and the content is enough to activate the resumption of meiosis. These lines of evidence suggest that the expression of ovarian CYP51 is dependent on gonadotropins, and ovarian CYP51 activity is enough for accumulating MAS. Serum insulin does not affect the ovarian CYP51 level, although it is essential for hepatic CYP51 expression. These findings indicate that expression of CYP51 is regulated differently among organs.
authors.affiliation: School of Pharmaceutical Sciences and Institute for Bioscience, Mukogawa Women's University, Nishinomiya 663-8179, Japan.
authors.forename: C
authors.initials: C
authors.lastname: Yamashita
authors.forename: Y
authors.initials: Y
authors.lastname: Aoyama
authors.forename: M
authors.initials: M
authors.lastname: Noshiro
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshida
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis*; D005260:Female; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D006062:Gonadotropins / Q000494:pharmacology*; D006064:Gonadotropins, Equine / Q000494:pharmacology; D022781:Hepatocytes / Q000201:enzymology; D007016:Hypophysectomy / Q000009:adverse effects; D008540:Meiosis / Q000502:physiology; D010053:Ovary / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D010088:Oxidoreductases / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012741:Sexual Maturation / Q000502:physiology; D058886:Sterol 14-Demethylase; D013261:Sterols / Q000378:metabolism*; D013311:Streptozocin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D006063:Chorionic Gonadotropin; C548417:Cyp51 protein, rat; D006062:Gonadotropins; D006064:Gonadotropins, Equine; D013261:Sterols; D013311:Streptozocin; D003577:Cytochrome P-450 Enzyme System; D010088:Oxidoreductases; D058886:Sterol 14-Demethylase